Trial Profile
Effect of a Potent CYP3A and P-gp Inhibitor (Itraconazole) on Ipatasertib Pharmacokinetics in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Ipatasertib (Primary) ; Itraconazole
- Indications Breast cancer; Gastrointestinal cancer; Prostate cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Roche
- 07 Nov 2017 Status changed from recruiting to completed.
- 21 Jul 2017 New trial record